Metastatic melanoma – A review of current and future treatment options

Acta Dermato-Venereologica

Volumn 95, Issue 5, 2015, Pages 516-524

  Maverakis, Emanual ^a,b   Cornelius, Lynn A ^c   Bowen, Glen M ^d   Phan, Tiffany ^a   Patel, Falin B ^a   Fitzmaurice, Sarah ^a   He, Young ^a   Burrall, Barbara ^a   Duong, Christopher ^a   Kloxin, April M ^e   Sultani, Hawa ^a   Wilken, Reason ^a   Martinez, Steve R ^f   Patel, Forum ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Northern California Veteran's Healthcare System   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF DELAWARE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CTLA 4; IL 2; PD 1; Stage III; Stage IV

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; CANCER VACCINE; DABRAFENIB; DENDRITIC CELL VACCINE; IMIQUIMOD; NIVOLUMAB; PEMBROLIZUMAB; RECOMBINANT INTERLEUKIN 2; TALIMOGENE LAHERPAREPVEC; VEMURAFENIB; BIOLOGICAL PRODUCT; INTERFERON;

ADOPTIVE IMMUNOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CELL THERAPY; CRYOTHERAPY; DRUG MEGADOSE; HUMAN; IMMUNOTHERAPY; LIMB PERFUSION; METASTASIS; METASTATIC MELANOMA; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TREATMENT PLANNING; CANCER REGISTRY; CHEMOSURGERY; FEMALE; INTRALESIONAL DRUG ADMINISTRATION; MALE; MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SECONDARY; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR INVASION;

BIOLOGICAL PRODUCTS; CANCER VACCINES; CLINICAL TRIALS, PHASE I AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRALESIONAL; INTERFERONS; MALE; MELANOMA; MOHS SURGERY; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEER PROGRAM; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84928158616     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-2035     Document Type: Review

References (118)

1. Sosman J, Kim K, Schuchter L, Gonzalez R, Pavlick A, Weber J, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-714.
2. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
3. Weide B, Faller C, Buttner P, Pflugfelder A, Leiter U, Eigentler TK, et al. Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis. PloS One 2013; 8: e63137.
4. Younes R, Abrao FC, Gross J. Pulmonary metastasectomy for malignant melanoma: prognostic factors for long-term survival. Melanoma Res 2013; 23: 307-311.
5. Wong J, Skinner K, Kim K, Foshag L, Morton D. The role of surgery in the treatment of nonregionally recurrent melanoma. Surgery 1993; 113: 389-394.
6. Sosman JA, Moon J, Tuthill RJ, Warneke JA, Vetto JT, Redman BG, et al. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer 2011; 117: 4740-4706.
7. Morton DL, Mozzillo N, Thompson JF, Kelley MC, Faries M, Wagner S, et al. An international, randomized, doubleblind, phase 3 study of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol 2007; 25: Abstract 8508.
8. Cumberlin R, DeMoss E, Lassus M, Friedman M. Isolation perfusion for malignant melanoma of the extremity: A review. J Clin Oncol 1985; 3: 1022-1031.
9. Bhuyan B. Kinetics of cell kill by hyperthermia. Cancer Res 1979; 39: 2277-2284.
10. Hahn G, Shiu E. Effects of pH and elevated temperature on the cytotoxicity of some chemotherapeutic agents on chinese hamster cells in vitro. Cancer Res 1983; 43: 5789-5791.
11. Oleson J, Calderwood S, Coughlin C, Dewhirst M, Gerweck L, Gibbs Jr F, et al. Biological and clinical aspects of hyperthermia in cancer therapy. Am J Clin Oncol 1988; 11: 368-380.
12. Fraker D, Alexander H, Ross R. A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus TNFalpha plus IFNgamma. Ann Surg Oncol 2002; 9: S8.
13. Cornett WR, McCall LM, Petersen RP, Ross MI, Briele HA, Noyes RD, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006; 24: 4196-4201.
14. Moreno-Ramireza D, Cruz-Merinob L, Ferrandiza L, Villegas-Porteroc R, Adoracion N. Isolated limb perfusion for malignant melanoma: systemic review on effectiveness and safety. Oncologist 2010; 15: 416-427.
15. Lens MB, Dawes M. Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systemic review of randomised controlled trials. Lancet Oncol 2003; 4: 359-364.
16. Lingam M, Byrnes D, Aitchison T, MacKie R, McKay A. A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb. Eur J Cancer 1996; 32A: 1668-1673.
17. Giles MH, Coventry BJ. Isolated limb infusion chemotherapy for melanoma: an overview of early experience at the Adelaide Melanoma Unit. Cancer Manag Res 2013; 5: 243-249.
18. John HE, Mahaffey PJ. Laser ablation and cryotherapy of melanoma metastases. J Surg Oncol 2014; 109: 296-300.
19. Bouchlaka MN, Sckisel GD, Wilkins D, Maverakis E, Monjazeb AM, Fung M, et al. Mechanical disruption of tumors by iron particles and magnetic field application results in increased anti-tumor immune responses. PloS One 2012; 7: e48049.
20. Delaney G, Barton M, Jacob S. Estimation of an optimal radiotherapy utilization rate for melanoma: a review of the evidence. Cancer 2004; 100: 1293-1301.
21. Olivier KR, Schild SE, Morris CG, Brown PD, Markovic SN. A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer 2007; 110: 1791-1795.
22. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004; 58: 862-870.
23. Seung SK, Curti BD, Crittenden M, Walker E, Coffey T, Siebert JC, et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2 - tumor and immunological responses. Sci Transl Med 2012; 4: 137ra174.
24. Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
25. Flaherty K, Puzanov I, Kim K, Ribas A, McArthur G, Sosman J, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-819.
26. Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradign in melanoma. Nat Rev Clin Oncol 2011; 8: 426-433.
27. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365.
28. Chapman P, Hauschild A, Robert C, Haanen J, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
29. Alcala AM, Flaherty KT. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. Clin Cancer Res 2012; 18: 33-39.
30. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013; 31: 1767-1774.
31. Wilmott JS, Tembe V, Howle JR, Sharma R, Thompson JF, Rizos H, et al. Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. Mol Cancer Ther 2012; 11: 2704-2708.
32. Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, et al. Preexisting MEK1 exon 3 mutations in V600E/ KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov 2012; 2: 414-424.
33. Lo RS. Receptor tyrosine kinases in cancer escape from BRAF inhibitors. Cell Res 2012; 22: 945-947.
34. Flaherty K, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-114.
35. Yamamoto T, Ueta E, Osaki T. Apoptosis induction by interleukin-2-activated cytotoxic lymphocytes in a squamous cell carcinoma cell line and Daudi cells - involvement of reactive oxygen species-dependent cytochrome c and reactive oxygen species-independent apoptosisinducing factors. Immunology 2003; 110: 217-224.
36. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105-2116.
37. Green DS, Bodman-Smith MD, Dalgleish AG, Fischer MD. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 2007; 156: 337-345.
38. Weide B, Derhovanessian E, Pflugfelder A, Eigentler TK, Radny P, Zelba H, et al. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 2010; 116: 4139-4146.
39. Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003; 89: 1620-1626.
40. Boyd KU, Wehrli BM, Temple CL. Intra-lesional interleukin- 2 for the treatment of in-transit melanoma. J Surg Oncol 2011; 104: 711-717.
41. Garcia M, Ono Y, Martinez S, Chen S, Goodarzi H, Phan T, et al. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream. Melanoma Res 2011; 21: 235-243.
42. Wei S, Kryczek I, Edwards RP, Zou L, Szeliga W, Banerjee M, et al. Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res 2007; 67: 7487-7494.
43. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP, 3rd, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011; 365: 2055-2066.
44. Green D, Dalgleish A, Belonwu N, Fischer M, Bodman- Smith M. Topical imiquimod and intralesional interleukin- 2 increase activated lymphocytes and restore the Th1/ Th2 balance in patients with metastatic melanoma. Br J Dermatol 2008; 159: 606-614.
45. Balch CM, Soong SJ, Smith T, Ross MI, Urist MM, Karakousis CP, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001; 8: 101-108.
46. Dillman R, O'Connor A, Simpson L, Barth N, Vander- Molen L, Vanderplas P. Does continuous-infusion interleukin- 2 increase survival in metastatic melanoma? Am J Clin Oncol 2003; 26: 141-145.
47. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunol 2002; 3: 196-200.
48. Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005; 174: 1259-1268.
49. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41: 1002-1007.
50. Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001; 44: 462-470.
51. Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol 1998; 134: 25-30.
52. Suchin KR, Junkins-Hopkins JM, Rook AH. Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod. Arch Dermatol 2002; 138: 1137-1139.
53. Deeths MJ, Chapman JT, Dellavalle RP, Zeng C, Aeling JL. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol 2005; 52: 275-280.
54. Zampogna JC, Flowers FP, Roth WI, Hassenein AM. Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: two case reports. J Am Acad Dermatol 2002; 47: S229-235.
55. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 2000; 143: 843-845.
56. Steinmann A, Funk JO, Schuler G, von den Driesch P. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 2000; 43: 555-556.
57. Naylor MF, Crowson N, Kuwahara R, Teague K, Garcia C, Mackinnis C, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003; Suppl 66: 66-70.
58. Bong AB, Bonnekoh B, Franke I, Schon MP, Ulrich J, Gollnick H. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 2002; 205: 135-138.
59. Turza K, Dengel LT, Harris RC, Patterson JW, White K, Grosh WW, et al. Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. J Cutan Pathol 2009; 37: 94-98.
60. Schon MP, Wienrich BG, Drewniok C, Bong AB, Eberle J, Geilen CC, et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 2004; 122: 1266-1276.
61. Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, Tomai MA, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000; 114: 135-141.
62. Burns RP, Jr., Ferbel B, Tomai M, Miller R, Gaspari AA. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol 2000; 94: 13-23.
63. Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 2002; 218: 74-86.
64. Dusza SW, Delgado R, Busam KJ, Marghoob AA, Halpern AC. Treatment of dysplastic nevi with 5% imiquimod cream, a pilot study. J Drugs Dermatol 2006; 5: 56-62.
65. Proctor JW, Zidar B, Pomerantz M, Yamamura Y, Eng CP, Woodside D. Anaphylactic reaction to intralesional B.C.G. Lancet 1978; 2: 162.
66. Moff SL, Corey GR, Gottfredsson M. Distant cutaneous granulomas after bacille Calmette-Guerin immunotherapy for malignant melanoma: case for direct infection. Clin Infect Dis 1999; 29: 1569-1570.
67. Kolmel KF, Grange JM, Krone B, Mastrangelo G, Rossi CR, Henz BM, et al. Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur J Cancer 2005; 41: 118-125.
68. Krone B, Kolmel KF, Henz BM, Grange JM. Protection against melanoma by vaccination with Bacille Calmette- Guerin (BCG) and/or vaccinia: an epidemiology-based hypothesis on the nature of a melanoma risk factor and its immunological control. Eur J Cancer 2005; 41: 104-117.
69. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Ann Rev Immunol 2005; 23: 307-336.
70. Werdin F, Tennenhaus M, Schaller HE, Rennekampff HO. Evidence-based management strategies for treatment of chronic wounds. Eplasty 2009; 4: e19.
71. Pirard D, Heenen M, Melot C, Vereecken P. Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis. Dermatology 2004; 208: 43-48.
72. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003; 29: 241-252.
73. Garbe C, Radny P, Linse R, Dummer R, Gutzmer R, Ulrich J, et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol 2008; 19: 1195-1201.
74. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372: 117-126.
75. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010; 102: 493-501.
76. Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012; 48: 218-225.
77. Turner ML, Moshell AN, Corbett DW, Stern JB, Roth MJ, DiGiovanna J, et al. Clearing of melanoma in situ with intralesional interferon alfa in a patient with xeroderma pigmentosum. Arch Dermatol 1994; 130: 1491-1494.
78. Cornejo P, Vanaclocha F, Polimon I, Del Rio R. Intralesional interferon treatment of lentigo maligna. Arch Dermatol 2000; 136: 428-430.
79. Carucci JA, Leffell DJ. Intralesional interferon alfa for treatment of recurrent lentigo maligna of the eyelid in a patient with primary acquired melanosis. Arch Dermatol 2000; 136: 1415-1416.
80. Ulmer A, Metzger S, Fierlbeck G. Successful palliation of stenosing anorectal melanoma by intratumoral injections with natural interferon-beta. Melanoma Res 2002; 12: 395-398.
81. Rapprich H, Hagedorn M. Intralesional therapy of metastatic spreading melanoma with beta-interferon. J Dtsch Dermatol Ges 2006; 4: 743-746.
82. Paul E, Muller I, Renner H, Bodeker RH, Cochran AJ. Treatment of locoregional metastases of malignant melanomas with radiotherapy and intralesional beta-interferon injection. Melanoma Res 2003; 13: 611-617.
83. Kawada K, Kawano T, Nagai K, Nishikage T, Nakajima Y, Tokairin Y, et al. Local injection of interferon beta in malignant melanoma of the esophagus as adjuvant of systemic pre- and postoperative DAV chemotherapy: case report with 7 years of long-term survival. Gastrointest Endosc 2007; 66: 408-410.
84. Fujimura T, Okuyama R, Ohtani T, Ito Y, Haga T, Hashimoto A, et al. Perilesional treatment of metastatic melanoma with interferon-beta. Clin Exp Dermatol 2009; 34: 793-799.
85. Chung MH, Gupta RK, Hsueh E, Essner R, Ye W, Yee R, et al. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy. J Clin Oncol 2003; 21: 313-319.
86. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011; 364: 2119-2127.
87. Whiteside TL, Schuler P, Schilling B. Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther 2012; 12: 1383-1397.
88. Carreno BM, Becker-Hapak M, Huang A, Chan M, Alyasiry A, Lie WR, et al. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Inv 2013; 123: 3383-3394.
89. Sercarz EE, Maverakis E. Mhc-guided processing: binding of large antigen fragments. Nat Rev Immunol 2003; 3: 621-629.
90. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003; 10: 292-303.
91. Toda M, Martuza RL, Rabkin SD. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colonystimulating factor. Mol Ther 2000; 2: 324-329.
92. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIC and IV melanoma. Ann Surg Oncol 2010; 17: 718-730.
93. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpesvirus in unresectable metastatic melanoma. J Clin Oncol 2008; 26: abstr 9008.
94. Kaufman HL, Bines SD. OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol 2010; 6: 941-949.
95. Barth RJJ, Mule JJ, Spiess PJ, et al. Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. J Immunol 1990; 144: 1531-1537.
96. Barth RJJ, Mule JJ, Spiess PJ, et al. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 1991; 173: 647-658.
97. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumorinfiltrating lymphocytes. Science 1986; 233: 1318-1321.
98. Spiess PJ, Yang J, Rosenberg SA. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Nat Cancer Inst 1987; 79: 1067-1075.
99. Yang JC, Perry-Lalley D, Rosenberg SA. An improved method for growing murine tumor-infiltrating lymphocytes with an in vivo antihumor activity. J Biol Response Mod 1990; 9: 149-159.
100. Rosenberg S, Yannelli J, Yang J, Topalian S, Schwartzentruber D, Weber J, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Nat Cancer Inst 1994; 86: 1159-1166.
101. Dudley M, Wunderlich J, Yang J, Sherry R, Topalian S, Restifo N, et al. Adoptive cell transfer therapy following non-myeloblative but lymphodepleting chemotherapy for the treatment of patients with refractory metastic melanoma. J Clin Oncol 2005; 23: 2346-2357.
102. Rosenberg S, Yang J, Sherry R, Kammula U, Hughes M, Phan G, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy. Clin Cancer Res 2011; 17: 4550-4557.
103. Morgan R, Dudley M, Wunderlich J, Hughes M, Yang J, Sherry R, et al. Cancer regression in pnatients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129.
104. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005; 23: 8968-8977.
105. Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009; 27: 1075-1081.
106. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 2009; 23: 488-496.
107. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte- associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003; 100: 4712-4717.
108. Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist 2008; 13 Suppl 4: 16-25.
109. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006; 18: 206-213.
110. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23: 6043-6053.
111. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013; 31: 616-622.
112. Hodi F, O'Day S, McDermott D, Weber R, Sosman J, Haanen J, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
113. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
114. Sarnaik AA, Yu B, Yu D, Morelli D, Hall M, Bogle D, et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res 2011; 17: 896-906.
115. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012; 18: 2039-2047.
116. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-133.
117. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384: 1109-1117.
118. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-144.